BerGenBio Initiates Clinical Trial for Promising Lung Cancer Treatment

BerGenBio ASA ( (BRRGF) ) has issued an announcement.

BerGenBio ASA announced that the first patient has been enrolled in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio. The trial aims to investigate the efficacy of BerGenBio’s bemcentinib in combination with pacritinib for treating advanced lung cancer, particularly focusing on patients with lung adenocarcinoma. The research, led by Dr. Josephine A. Taverna, explores the potential of AXL and JAK-STAT3 pathways in promoting tumor growth and metastasis, aligning with BerGenBio’s strategic focus on addressing unmet needs in lung cancer treatment. This development could enhance the company’s positioning in the biopharmaceutical industry by potentially offering new treatment options for lung cancer patients.

More about BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company headquartered in Bergen, Norway, with a subsidiary in Oxford, UK. The company focuses on developing transformative drugs targeting AXL, particularly for aggressive diseases such as cancer. Its lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in development for STK11 mutated non-small cell lung cancer (NSCLC). BerGenBio is publicly traded on the Oslo Stock Exchange under the ticker BGBIO.

YTD Price Performance: 0%

Average Trading Volume: 37,305

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $31.33M

See more insights into BRRGF stock on TipRanks’ Stock Analysis page.